OBJECTIVE: We performed an open-label Phase I/II trial to evaluate the safety and tolerability of vagus nerve stimulation (VNS) in patients with treatment-resistant fibromyalgia (FM) as well as to determine preliminary measures of efficacy in these patients. METHODS: Of 14 patients implanted with the VNS stimulator, 12 patients completed the initial 3-month study of VNS; 11 patients returned for follow-up visits 5, 8, and 11 months after start of stimulation. Therapeutic efficacy was assessed with a composite measure requiring improvement in pain, overall wellness, and physical function. Loss of both pain and tenderness criteria for the diagnosis of FM was added as a secondary outcome measure because of results found at the end of 3 months of stimulation. RESULTS: Side effects were similar to those reported in patients treated with VNS for epilepsy or depression and, in addition, dry mouth and fatigue were reported. Two patients did not tolerate stimulation. At 3 months, five patients had attained efficacy criteria; of these, two patients no longer met widespread pain or tenderness criteria for the diagnosis of FM. The therapeutic effect seemed to increase over time in that additional participants attained both criteria at 11 months. CONCLUSIONS: Side effects and tolerability were similar to those found in disorders currently treated with VNS. Preliminary outcome measures suggested that VNS may be a useful adjunct treatment for FM patients resistant to conventional therapeutic management, but further research is required to better understand its actual role in the treatment of FM. Wiley Periodicals, Inc.
OBJECTIVE: We performed an open-label Phase I/II trial to evaluate the safety and tolerability of vagus nerve stimulation (VNS) in patients with treatment-resistant fibromyalgia (FM) as well as to determine preliminary measures of efficacy in these patients. METHODS: Of 14 patients implanted with the VNS stimulator, 12 patients completed the initial 3-month study of VNS; 11 patients returned for follow-up visits 5, 8, and 11 months after start of stimulation. Therapeutic efficacy was assessed with a composite measure requiring improvement in pain, overall wellness, and physical function. Loss of both pain and tenderness criteria for the diagnosis of FM was added as a secondary outcome measure because of results found at the end of 3 months of stimulation. RESULTS: Side effects were similar to those reported in patients treated with VNS for epilepsy or depression and, in addition, dry mouth and fatigue were reported. Two patients did not tolerate stimulation. At 3 months, five patients had attained efficacy criteria; of these, two patients no longer met widespread pain or tenderness criteria for the diagnosis of FM. The therapeutic effect seemed to increase over time in that additional participants attained both criteria at 11 months. CONCLUSIONS: Side effects and tolerability were similar to those found in disorders currently treated with VNS. Preliminary outcome measures suggested that VNS may be a useful adjunct treatment for FM patients resistant to conventional therapeutic management, but further research is required to better understand its actual role in the treatment of FM. Wiley Periodicals, Inc.
Authors: Stuart J Connolly; Robert Sheldon; Kevin E Thorpe; Robin S Roberts; Kenneth A Ellenbogen; Bruce L Wilkoff; Carlos Morillo; Michael Gent Journal: JAMA Date: 2003-05-07 Impact factor: 56.272
Authors: Cynthia McRae; Eva Cherin; T Gayle Yamazaki; Gretchen Diem; Alexander H Vo; Dan Russell; J Heiner Ellgring; Stanley Fahn; Paul Greene; Sandra Dillon; Hal Winfield; Kimberly B Bjugstad; Curt R Freed Journal: Arch Gen Psychiatry Date: 2004-04
Authors: J Bruce Moseley; Kimberly O'Malley; Nancy J Petersen; Terri J Menke; Baruch A Brody; David H Kuykendall; John C Hollingsworth; Carol M Ashton; Nelda P Wray Journal: N Engl J Med Date: 2002-07-11 Impact factor: 91.245
Authors: F Wolfe; H A Smythe; M B Yunus; R M Bennett; C Bombardier; D L Goldenberg; P Tugwell; S M Campbell; M Abeles; P Clark Journal: Arthritis Rheum Date: 1990-02
Authors: Jon I Russell; Philip J Mease; Timothy R Smith; Daniel K Kajdasz; Madelaine M Wohlreich; Michael J Detke; Daniel J Walker; Amy S Chappell; Lesley M Arnold Journal: Pain Date: 2008-04-18 Impact factor: 6.961
Authors: Heberto Suarez-Roca; Rebecca Y Klinger; Mihai V Podgoreanu; Ru-Rong Ji; Martin I Sigurdsson; Nathan Waldron; Joseph P Mathew; William Maixner Journal: Anesthesiology Date: 2019-04 Impact factor: 7.892
Authors: Hailley Loper; Monique Leinen; Logan Bassoff; Jack Sample; Mario Romero-Ortega; Kenneth J Gustafson; Dawn M Taylor; Matthew A Schiefer Journal: Sci Rep Date: 2021-05-17 Impact factor: 4.996
Authors: Ronald Sahyouni; David T Chang; Omid Moshtaghi; Amin Mahmoodi; Hamid R Djalilian; Harrison W Lin Journal: Laryngoscope Investig Otolaryngol Date: 2017-02-06